What's On

Join us for an Online Industry Insight on Medical Research

with Medigrowth on Thursday 23 October at 12pm.

Medigrowth Australia is a clinical-stage biopharmaceutical company developing ARTG-registered cannabinoid medicines. Its lead program targets Autism Spectrum Disorder (ASD), with Phase I/II trials complete and the Phase III protocol ready to commence.

Beyond ASD, Medigrowth’s pipeline interest includes cachexia, anxiety, aged care, and Indigenous health, reflecting a broad commitment to unmet medical needs.

The companypartners with leading institutions including Deakin University and theUniversity of Western Australia (UWA), ensuring its programs are built onstrong scientific collaboration.

Commercially,Medigrowth operates a growing distribution business of approved unregisteredmedicines, enhanced by digital and data-driven initiatives that better supportresearchers, practitioners, pharmacists, and patients. 

The company is also preparing for international exports, backed by ARTG listings and planning forclinical trials in emerging markets.

Committed to a future in theCity of Greater Geelong, Medigrowth has secured approval for a Centre of Excellence co-located with Deakin University’s Waurn Ponds campus—a hub forresearch, manufacturing and innovation.